Viropharma - hochspekulativer Geheimtipp!


Seite 1 von 1
Neuester Beitrag: 07.01.10 00:24
Eröffnet am:14.12.07 19:56von: bullish987Anzahl Beiträge:21
Neuester Beitrag:07.01.10 00:24von: ipollitLeser gesamt:4.731
Forum:Hot-Stocks Leser heute:1
Bewertet mit:
1


 

70 Postings, 5990 Tage bullish987Viropharma - hochspekulativer Geheimtipp!

 
  
    #1
1
14.12.07 19:56
Fundamental

Viropharma hatte bis ins Jahr 2000 hinein einen hochinteressanten Impfstoff in der Entwicklung, der jedoch in den klinischen Phasen scheiterte. Daraufhin wurde die Aktie natürlich in den Keller geschickt und mutierte lange Zeit sogar zu einem sogenannten Pennystock.
Doch nach einiger Zeit schaffte man es durch Einlizenzierung neuer Medikamente sowie der Weiterentwicklung von eigenen Medikamenten, den Turn-Around hinzubekommen. So wächst das Unternehmen schon seit einiger Zeit sowohl beim Umsatz wie auch beim Gewinn deutlich und der Aktienkurs konnte deutlich zulegen.
Seit einiger Zeit jedoch hat die Aktie den Rückwärtsgang eingelegt und ist aktuell so billig wie zuletzt vor etwa einem Jahr. So wird das Unternehmen aktuell mit einem KUV von etwa 1 und einem KGV von gerade mal 7 bewertet, was für ein profitabel wachsendes Biotechunternehmen in den USA als sehr günstig einzustufen ist. Somit ist die Aktie fundamental ganz klar mit STRONG BUY einzustufen...


Charttechnik

Wie eben schon geschrieben, ist die Aktie aktuell auf den Stand von vor einem Jahr zurückgekommen. Damit sieht alles nach der Ausbildung eines Doppelbodens aus. Von diesem ausgehend könnte es dann wieder deutlich aufwärts gehen. Die günstige Bewertung spricht sicherlich dafür, dass die Bodenbildung gelingen könnte. Die Charttechnik jedoch deutet nicht unbedingt darauf hin. Denn auf dem Weg nach oben stehen nicht nur sämtliche Gleitenden Durchschnitte im Wege, sondern auch die Indikatorenlage ist noch bestenfalls als neutral einzustufen. Aus charttechnischer Sicht ist die Viropharma Aktie daher eine Halteposition.


Sentimentbetrachtung

Zur Betrachtung der Stimmungslage habe ich heute mal einen neuartigen Chart mitgebracht, der neben dem Kursverlauf auch alle Empfehlungen der letzten Zeit enthält.



Wie man erkennen kann, beobachten nur sehr wenige Analysten diese Aktie. Die wenigen Analysten, die die Aktie aber beobachten, sind alle positiv gestimmt. Das Sentiment ist daher für einen Anstieg eigentlich zu positiv, aber da nur wenige Analysten die Aktie auf dem Radar haben ist dies wenig aussagekräftig. Somit schenke ich dem Sentiment hier wenig Bedeutung.


Ergebnis der Analysen

Fundamental ist die Viropharma Aktie mit einem KUV von 1 und einem KGV von 7 ein klarer Kauf. Vergleichbare Unternehmen werden in den USA normalerweise mit KUVs von 3 bis 4 und KGVs von 40 und mehr bewertet. Charttechnisch ist die Aktie angeschlagen, aber noch ist alles in Ordnung. Das eigentlich zu gute Sentiment ist in diesem Fall bedeutungslos, da einfach zu wenige Analysten die Company überhaupt verfolgen.
Ich vergebe daher folgende Einschätzungen für die Biotechcompany Viropharma: SHORT TERM STRONG BUY SPECULATIVE, Price Target: 8 Euro und LONG TERM STRONG BUY SPECULATIVE, Price Target: 10 Euro. Denn Stoppkurs muss man in diesem Fall jedoch sehr eng unter den aktuellen Kursen platzieren - also bei knapp unter 5 Euro. Somit kann man die Chancen nach oben ggfs. nutzen und das bei einem sehr niedrigen Risiko von maximal ca. 5%.
Wichtig ist jedoch, dass man diesen engen Stoppkurs konsequent einhält!  

3656 Postings, 7334 Tage Bäcker33ViroPharma "buy"

 
  
    #2
04.06.08 16:56
Stanford Financial Group - ViroPharma "buy"
16:09 03.06.08

Rating-Update:

Houston (aktiencheck.de AG) - Die Analysten von Stanford Financial Group stufen die Aktie von ViroPharma (Profil) in einer Ersteinschätzung mit "buy" ein. Das Kursziel werde bei 13 USD gesehen. (03.06.2008/ac/a/u)
 

3656 Postings, 7334 Tage Bäcker33Wichtiger Termin

 
  
    #3
04.06.08 17:22
ViroPharma to Present at Two Upcoming Healthcare Conferences


Last update: 2:02 p.m. EDT June 3, 2008
EXTON, Pa., June 3, 2008 /PRNewswire-FirstCall via COMTEX/ -- ViroPharma Incorporated (VPHM:VPHM
News, chart, profile, more
Last:


Delayed quote dataAdd to portfolio
Analyst
Create alertInsider
Discuss
Financials
Sponsored by:
VPHM, , ) today announced that Vincent Milano, president and chief executive officer of ViroPharma, will present at the Goldman Sachs 29th Annual Global Healthcare Conference at 4:00 P.M. PDT on Tuesday, June 10, 2008. The conference is being held at the Ritz-Carlton, Laguna Nigel in Dana Point, CA.
ViroPharma also announced that William Roberts, vice president, corporate communications of ViroPharma, will present at the Needham Seventh Annual Biotechnology and Medical Technology Conference at 8:00 A.M. EDT on Wednesday, June 11, 2008. The conference is being held at the New York Palace Hotel.
ViroPharma's presentations will be webcast live for investors through http://www.viropharma.com and available for a period of 14 days following the conferences.
About ViroPharma Incorporated
ViroPharma Incorporated is a biopharmaceutical company dedicated to the development and commercialization of products that address serious diseases treated by physician specialists and in hospital settings. ViroPharma commercializes Vancocin(R), approved for oral administration for treatment of antibiotic-associated pseudomembranous colitis caused by Clostridium difficile and enterocolitis caused by Staphylococcus aureus, including methicillin-resistant strains (for prescribing information, please download the package insert at http://www.viropharma.com/Products.aspx). ViroPharma currently focuses its drug development activities in diseases including cytomegalovirus (CMV) and Clostridium difficile. For more information on ViroPharma, visit the company's website at http://www.viropharma.com.
SOURCE ViroPharma Incorporated
http://www.viropharma.com

Copyright (C) 2008 PR Newswire. All rights reserved  

1895 Postings, 7602 Tage DERDAXheute chartechnischer

 
  
    #4
04.06.08 19:55
ausbruch über 10dollar...bin zu 10,15 dabei  

3656 Postings, 7334 Tage Bäcker33Der Ausbruch

 
  
    #5
05.06.08 14:46
ist gestern gelungen! Mal schaun wie es heut weiter geht, könnt sich heut auch mal kurz stetzen!  
Angehängte Grafik:
virop.gif (verkleinert auf 77%) vergrößern
virop.gif

1895 Postings, 7602 Tage DERDAXrücksetzer

 
  
    #6
05.06.08 16:16
können kommen...solange der kurs über 10,00 bleibt ist der uptrend intakt  

1895 Postings, 7602 Tage DERDAXSK 10,99

 
  
    #7
05.06.08 23:35
+6% bei weiter starken volumen und guten newsflow  

1855 Postings, 6705 Tage PlisconNachbörslich in den USA fett im Minus!

 
  
    #8
06.06.08 00:08
VIROPHARMA INC
(NasdaqGS: VPHM)

After Hours: 9.91 Down-1.08 (-9.83%) 5:23pm ET  

1895 Postings, 7602 Tage DERDAXsieht nach einer

 
  
    #9
06.06.08 01:21
fake order aus...gestern das gleiche Spiel...gibt zumindestens keine negativen nachrichten nachbörslich...naja,morgen abend wissen wir mehr  

3656 Postings, 7334 Tage Bäcker33SK

 
  
    #10
06.06.08 11:04
war auf TH  
Angehängte Grafik:
viro2.gif (verkleinert auf 70%) vergrößern
viro2.gif

3656 Postings, 7334 Tage Bäcker33Research and Markets

 
  
    #11
06.06.08 11:27
Research and Markets: Complete and Comprehensive Analysis of ViroPharma Inc. and Their Competitors


Last update: 10:00 a.m. EDT June 5, 2008

DUBLIN, Ireland, Jun 05, 2008 (BUSINESS WIRE) -- Research and Markets ( http://www.researchandmarkets.com/reports/c93803) has announced the addition of "Analysis of ViroPharma Inc." to their offering.
We present Analysis of ViroPharma Inc. A complete and comprehensive analysis of ViroPharma Inc. includes an overview of the industry the company operates in, a PEST Framework Analysis of the industry, and then moves on to analyzing the company itself.
Company analysis includes a history of ViroPharma Inc., a business segment analysis of the segments ViroPharma Inc. operates through, a look at the organization structure of the company, a geographical operating segments analysis, and an analysis of the company's major competitors.
A financial analysis of ViroPharma Inc. is presented in the report which includes a ratio analysis, basic profit and loss analysis, presentation of the company balance sheet, and much more.
A SWOT Framework Analysis of ViroPharma Inc. completes this in-depth company analysis.
Key Topics:
- Executive Summary
- Looking at the Industry
- Industry PEST Framework Analysis
- Looking at the Company
- Looking at Business
- SWOT Framework Analysis
- Profiling the Competition
- Financial Analysis of the Company
- Future Perspective
- Appendix
- Glossary of Terms
Competitors mentioned:
- Amgen Inc.
- Gilead Sciences Inc.
For more information visit http://www.researchandmarkets.com/reports/c93803.
SOURCE: Research and Markets Ltd.
Research and Markets
Laura Wood, Senior Manager
Fax: +353 1 4100 980
press@researchandmarkets.com

Copyright Business Wire 2008
 

1895 Postings, 7602 Tage DERDAXdiese nachricht

 
  
    #12
06.06.08 11:31
dürfte die ursache für den kursanstieg gewesen sein...man spekuliert wohl, dass das blockbusterprodunkt vancocin nicht so schnell von generika-Herstellern produziert werden darf

ViroPharma comments on upcoming FDA advisory committee meeting; encouraged that FDA is taking this step to allow a critique of OGD's bioequivalence proposals Co notes that FDA has published a notice of a meeting of its Advisory Committee for Pharmaceutical Science and Clinical Pharmacology to be held on July 23, 2008. The Committee will address several issues at this meeting, including a discussion of: "presentations from the Office of Generic Drugs on the bioequivalence methods for locally acting drugs that treat gastrointestinal conditions..." Co says Clostridium difficile infection results in significant morbidity and mortality, and has developed into a national health issue. The risk to patients of a product that is not bioequivalent to Vancocin in this setting is high. "While the notice does not specifically identify Vancocin, ViroPharma intends to take every opportunity to ensure the points we've raised through our submissions will be brought forward to this committee."
 

1895 Postings, 7602 Tage DERDAXgerade gefunden

 
  
    #13
06.06.08 14:17
Viropharma Inc (VPHM) newly added by Growth Equity Fund

By: VINCENT JACOBS Approving Editor: JENNIFER THOMAS

LONG BEACH (Mffais.com) - Growth Equity Fund (Tiaa Cref Institutional Mutual Funds) added the Viropharma Inc (VPHM) company to their portfolio, by buying 113,288 shares as shown by filings made public on 2008-06-05.
The stock is currently owned by 241 funds/institutions with a total activity score of -0.12. With 40.78 % of owning funds reported recently buying shares, 11.40 % maintaining existing share level and 47.80 % selling shares. Full details for Viropharma Inc (VPHM) available at http://www.mffais.com/vphm.html  

3656 Postings, 7334 Tage Bäcker33ViroPharma Provides Update

 
  
    #14
08.07.08 15:51
ViroPharma Provides Update on Upcoming FDA Advisory Committee Meeting to Discuss Bioequivalence of Locally Acting Gastrointestinal Drugs


Last update: 9:00 a.m. EDT July 8, 2008
EXTON, Pa., July 8, 2008 /PRNewswire-FirstCall via COMTEX/ -- ViroPharma Incorporated (VPHM:VPHM
News, chart, profile, more
Last:


Delayed quote dataAdd to portfolio
Analyst
Create alertInsider
Discuss
Financials
Sponsored by:
VPHM, , ) has been informed by U.S. Food and Drug Administration (FDA) that the July 23, 2008 meeting of its Advisory Committee for Pharmaceutical Science and Clinical Pharmacology is not intended to discuss specifically ViroPharma's Vancocin(R) (vancomycin hydrochloride capsules) or any other drug products. Rather, FDA has informed ViroPharma that FDA's Office of Generic Drugs (OGD) will only present for the Committee's consideration issues of general applicability to all locally acting drugs that treat gastrointestinal (GI) conditions. FDA also informed ViroPharma that any resulting recommendations by the Committee will be similarly general in nature. Additionally, ViroPharma has been advised that it will be afforded no more time to speak at the meeting than is afforded to any other member of the public, consistent with the non-product specific focus of the meeting. ViroPharma understands that the time to be provided to any one speaker will be very limited.
Based on FDA's statements to ViroPharma regarding the purpose of this meeting, made by both Committee staff and FDA's Office of Chief Counsel, ViroPharma will not discuss Vancocin at this meeting. Given ViroPharma's experience in this area, and the limited time available to speakers at the meeting, ViroPharma today submitted a letter to the Committee to aid its consideration of the general issue of bioequivalence methods for locally acting GI drugs. Among other things, ViroPharma's letter notes important issues that must be addressed in this complex area of bioequivalence method development, and attaches for the Committee's review a letter sent to FDA last year by the Infectious Diseases Society of America (IDSA) expressing concerns of infectious disease experts. A copy of ViroPharma's letter and the attachment is now available on ViroPharma's website at http://www.viropharma.com/OGDpetition/.
FDA has indicated that ViroPharma can expect the opportunity for public input regarding bioequivalence methods for Vancocin, but has not yet committed to a next step. Commented Colin Broom, M.D., ViroPharma's vice president, chief scientific officer, "We are encouraged that FDA appears to be taking the first step toward a public process to consider the development of bioequivalence methods for locally acting drugs that treat gastrointestinal conditions. After the general discussion at the July 23rd Advisory Committee meeting, FDA should be better prepared to conduct a public process on bioequivalence methods for Vancocin specifically. ViroPharma is prepared to participate in that process when the time comes. We have long contended that changes in GI physiology observed in patients with Clostridium difficile infection make healthy gut bioequivalence models inapplicable to drugs, like Vancocin, which treat this condition."
ViroPharma has previously explained in various submissions to FDA that appropriate public process for development of bioequivalence methods specifically for Vancocin should include (1) public proposal of the method and the data FDA believes validate that method; (2) FDA receipt of and response to public comments on the proposed method; (3) consideration by the appropriate FDA Advisory Committees, including the Advisory Committee for Pharmaceutical Science and Clinical Pharmacology; and (4) final decision making on whether to adopt the method by neutral scientific and medical experts, not the FDA personnel who originally proposed the method. ViroPharma continues to believe that bioequivalence for Vancocin is deserving of at least the same level of process and scientific discussion that FDA has previously afforded locally acting GI drugs such as cholestyramine, mesalamine, and sucralfate that are used to treat far less serious diseases where the consequence associated with getting it wrong do not pose as great a risk to patients.
ViroPharma's filings detailing these requirements are available on ViroPharma's website at http://www.viropharma.com/OGDpetition/.
About Clostridium difficile
One of the most serious problems facing the U.S. healthcare system today is hospital-acquired infections (HAIs). Clostridium difficile infection is one of the most common and devastating HAIs. The incidence of C. difficile observed in U.S. healthcare facilities more than doubled between 2000 and 2005; between 1999 and 2004, reported mortality rates from C. difficile in the U.S. more than quadrupled to 23.7 per million. Elderly patients exposed to antibiotics, long-term care patients, or those that have a serious underlying illness, are at greatest risk to contract the disease. Patients with this disease have GI tract conditions that are significantly different from those of a healthy individual due to infection. Typical symptoms include diarrhea, fever, nausea and abdominal pain and dehydration, though cases can lead to life threatening complications such as megacolon, peritonitis and perforation of the colon.
About ViroPharma Incorporated
ViroPharma Incorporated is a biopharmaceutical company dedicated to the development and commercialization of products that address serious diseases treated by physician specialists and in hospital settings. ViroPharma commercializes Vancocin(R), approved for oral administration for treatment of antibiotic-associated pseudomembranous colitis caused by Clostridium difficile and enterocolitis caused by Staphylococcus aureus, including methicillin-resistant strains (for prescribing information, please download the package insert at http://www.viropharma.com/Products.aspx). ViroPharma currently focuses its drug development activities in diseases including cytomegalovirus (CMV) and C. difficile. For more information on ViroPharma, visit the company's website at http://www.viropharma.com.
Certain statements in this press release may contain forward-looking statements that involve a number of risks and uncertainties, including the Company's understanding that the meeting of the Advisory Committee for Pharmaceutical Science and Clinical Pharmacology is not intended to discuss specifically ViroPharma's Vancocin(R) and that additional opportunity for public input regarding bioequivalence methods for Vancocin will occur or that ViroPharma will ensure that the points in its letter to the advisory committee will be brought forward to this committee. There can be no assurance that the FDA will continue with its stated plans regarding the subject matter of the Advisory Committee meeting, that the FDA will conduct public process specifically for Vancocin, that the FDA will agree with the positions stated in ViroPharma's Vancocin related submissions or that ViroPharma's efforts to oppose the OGD's March 2006 recommendation to determine bioequivalence to Vancocin through in vitro dissolution testing will be successful. We cannot predict the timeframe in which the FDA will make a decision regarding either ViroPharma's citizen petition for Vancocin or the approval of generic versions of Vancocin. If we are unable to change the recommendation set forth by the OGD in March 2006, the threat of generic competition will be high. The entry of competing generic products will significantly affect our sales of Vancocin and our financial performance. Our actual results could differ materially from those results expressed in, or implied by, these forward-looking statements. These factors, and other factors, including, but not limited to those described in ViroPharma's annual report on Form 10-K and quarterly reports on Form 10-Q filed with the Securities and Exchange Commission during 2008 could cause future results to differ materially from the expectations expressed in this press release. The forward-looking statements contained in this press release may become outdated over time. ViroPharma does not assume any responsibility for updating any forward-looking statements.
SOURCE ViroPharma Incorporated
http://www.viropharma.com

Copyright (C) 2008 PR Newswire. All rights reserved
 

3656 Postings, 7334 Tage Bäcker33Atacke auf die

 
  
    #15
09.07.08 17:22
12$$ läuft  
Angehängte Grafik:
viro3.gif (verkleinert auf 64%) vergrößern
viro3.gif

3656 Postings, 7334 Tage Bäcker33So

 
  
    #16
11.07.08 16:24
12 $ wären platt :)

ariva.de  

3656 Postings, 7334 Tage Bäcker33Vphm

 
  
    #17
14.07.08 16:55

23601 Postings, 6171 Tage Chalifmann3Blockbuster Maribavir gescheitert !

 
  
    #18
10.02.09 17:01
Viropharma down 50 Prozent !

MFG
Chali  

21579 Postings, 6624 Tage JorgosImmerhin, der Titel hat sein Threadbeginn erst ein

 
  
    #19
10.02.09 17:06
Viertel an Wert verloren.
Bei dem Titel hatte ich vermutet, dass wir einen Kursverlust von mind. 90 % sehen.
Hat sich also bisher gut gehalten ! :;))

23601 Postings, 6171 Tage Chalifmann3Was

 
  
    #20
10.02.09 17:17
ham' die denn noch so in der Pipeline,kann mal einer die aktuellste Pipeline hier reinstellen ?!

Danke!

MFG
Chali  

749 Postings, 7518 Tage ipollitkein Problem... hier die aktuellste Pipeline!

 
  
    #21
07.01.10 00:24
 
Angehängte Grafik:
vphm.jpg (verkleinert auf 85%) vergrößern
vphm.jpg

   Antwort einfügen - nach oben